产品资料

Polyplus Transfection/in vivo-jetPEI^®/Polyplus Transfection-163153/1 Ea

Suitableforinvivodeliveryofanynucleicacid
ProvenTrackrecord:over700publications
Veryeasytouse:two-stepprotocol
Usedfortherapeuticsandclinicaltrialsworldwide
Safe:Noinflammatoryresponsetriggered
ProtocolstailoredforyourapplicationbyPolyplus-transfectiondeliveryexperts

Specifications:

Reagent	invivo-jetPEI^®
Moleculedelivered	DNA,siRNA,miRNA,Oligonucleotides,mRNA
Applications	invivofunctionalstudies Cancertherapy Vaccination/immunization Genomeediting
Targetedorgans	Allorgans
Injectionroutes	Systemicdelivery(Tailvein,intravenous,intraperitonealinjection) Localinjection
Numberoftransfections	100µlofinvivo-jetPEI^®deliveryreagentissufficienttoperform15to25intravenousinjectionsinmouse.
Storage	-20°C,foratleast12months
Providedwith	10%glucosesolution

Summary:

invivo-jetPEI^®isapowerfulpolymerbasedreagentusedtodeliveranynucleicacidtoanyanimalmodel.Theprotocolissimilartoaclassicaltransfection:thenucleicacidandthereagentarejustmixedandadmiNISTeredtotheanimal.

Orderinginformation:

|||201-10G##0.1ml##10ml##|||201-50G##0.5ml##2x10ml##|||

Description:

SuitableforinvivodeliveryofDNA,siRNA,miRNA,oligonucleotidesandmRNA

invivo-jetPEI^®isthereagentofchoicetodeliveranytypeofnucleicacidtomediategeneexpressionorgenesilencinginvarioustissues.ThesuccessofthisdeliverysystemreliesonitsABIlitytoefficientlydelivertheappropriatetherapeuticnucleicacidintothetargettissueorcellswithlowtoxicityandlimitedimmuneresponse.

invivo-jetPEI^®isveryversatileasitissuitableforthedeliveryofplasmidDNA(Fig.1),siRNA(Fig.2),shRNA,miRNA,oligonucleotidesandmRNA.

<em>invivo-jetPEI-ProteinexpressionfollowingplasmidDNAsystemicdelivery

Fig.1:ProteinexpressionfollowingplasmidDNAsystemicdeliveryusinginvivo-jetPEI^®.BioluminescentimagingofluciferaseexpressioninlivingNudemouseusingIVIS100camera(Caliper-Perkinelmer)24haftergenedelivery.pCMVLuc(50µg)wascomplexedwithinvivo-jetPEI^®in400µlof5%glucosesolutionandinjectedintothetailvein.

<em>invivo-jetPEI-siRNAmediatedsilencingofproteinexpressionusing<em>invivo</em>-jetPEI<sup>®</sup>(control).

<em>invivo-jetPEI-siRNAmediatedsilencingofproteinexpressionusing<em>invivo</em>-jetPEI<sup>®</sup>(anti-luc).

Fig.2:siRNAmediatedsilencingofproteinexpressionusinginvivo-jetPEI^®.BioluminescentimagingofluciferaseexpressioninlivingnudemiceusingacooledCCDcamera24hafterco-deliveryofplasmidDNAandsiRNA.pCMVLucplasmid(50µg)and10µgofsiRNA(left panel:controlsiRNA;right panel:anti-lucsiRNA)werecomplexedwithinvivo-jetPEI^®in400µlof5%glucosesolutionandinjectedintothetailvein.

Easytwo-stepprotocol

invivo-jetPEI^®isaveryeasy-to-usedeliveryreagent.Theprotocolconsistsinpreparingthenucleicacidandreagentseparatelyin5%glucosesolution,mixingthemtogetherandthen,aftera15minincubationtimeatroomtemperature,injectingthenucleicacid/invivo-jetPEI^®complexesformedintoanimal(Fig.3).Thisprotocolissuitableforanyadministrationrouteandanyanimalmodel.

Fig.3:invivo-jetPEI^®protocol.Convenientprotocolfordeliveryofanynucleicacid,usinganyrouteofadministrationinanyanimalmodel.

Widerangeofadministrationroutestotargetdifferentorgans

Thestabilityofinvivo-jetPEI^®/nucleicacidcomplexesallowstheuseofnumerousroutesofadministrationincludingsystemicorlocalinjection(Fig.4).

In vivo-jetPEI - Delivery routes — **Fig.4:Examplesofdeliveryroutesusinginvivo-jetPEIinmice.**

Therouteofadministrationlargelydeterminesthetargetedorgan.Forexampleuponintravenousinjection,invivo-jetPEI^®-mediatedDNAdeliveryleadstogeneexpressionmainlyinthelungbutalsointheliver,pancreas,spleen,kidney,heart,bladderandartery(Fig.5).

Inadditiontointravenousinjection,invivo-jetPEI^®isalsosuitableforlocaldeliveryroutessuchastopicalapplication,intracerebralorintra-articularinjections,anditisperfectfornucleicaciddeliveryintosubcutaneoustumormodels.

PossIBLetargetedorgansincludelungs,liver,brain,pancreas,spleen,kidney,heart,bladder,skin,retina,artery,etc.

Ourdeliveryspecialistsareavailabletoadaptourprotocoltoyourspecificapplicationandsendyoutherelevantliterature(Pleasecontactthetechnicalsupportteamatsupport@polyplus-transfection.com).Youmayalsodownloadguidelinesandprotocolsforinvivoexperimentsinmice,aswellastechnicalnotescontainingpublicationswithPolyplus-transfection^®reagentssortedbyadministrationrouteorbytargetedorgan/tissue(seeinattachedfilesbutton).

Suitableforanyanimalmodel

invivo-jetPEI^®isidealfornucleicaciddeliveryinmice.However,theprotocolissoeasyandversatilethatithasbeenadaptedtomanyotherspeciesincludingrat,guineapig,hamster,dog,rabbit,monkey,goat,sheep,cow,marmot,chicken,quail,duck,pigeon,gecko,tadpole,shrimp,zebrafish,abalone,snail,leech,mosquito…

Ourdeliveryexpertsareavailabletoadaptourprotocoltoyouranimalmodelandsendyoutherelevantliterature(Pleasecontactthetechnicalsupportteamatsupport@polyplus-transfection.com).

Currentlyusedfortherapeuticsandclinicaltrialsworldwide

invivo-jetPEI^®hasbeenselectedasadeliveryvectorforseveraldrugdevelopmentprogramsduetoitssafetyanddeliveryefficiency.TofulfillallthequalityrequirementsassociatedtotheuseofourreagentinHuman,Polyplus-transfection^®suppliespreclinicalgradereagents,aswellascGMPgradeinvivo-jetPEI^®thatarecurrentlyusedinseveralongoingpreclinicalstudiesand phaseIandIIclinicaltrials(Fig.6).

Fig.1: Clinical pipeline of ongoing preclinical and clinical trials using <em>invivo-jetPEI<sup>®</sup>. — **Fig.6:Clinicalpipelineofongoingpreclinicalandclinicaltrialsusinginvivo-jetPEI^®.**

Safe:noinflammatoryresponsetriggered

Followinginvivo-jetPEI^®-mediatedsystemicdeliveryofnucleicacid,thereisnoinductionofmajorpro-inflammatorycytokinesandnoincreaseinseralevelsofhepaticenzymes(Bonnetetal.(2008),PharmRes,25:2972)(Fig.6).Hence,invivo-jetPEI^®offersareliableandsafealternativetoviralvectorsthatcanelicitanimmuneresponse.

<em>invivo-jetPEI-Inflammatoryresponse — **Fig.7:Nopro-inflammatorycytokineinducedfollowingintravenousdeliveryofnucleicacid/*invivo*-jetPEI^®complexes**.AsiRNA(40ug)wasdeliveredwithorwithoutinvivo-jetPEI^®.ThelevelofTNF-α,IL12/IL23,IFNγandIL6wasmeasured1h,6h,12hand6hafterdelivery,respectively.Thenegativecontrolisglucoseonly,thepositivecontrolisanIPinjectionofE.coliLPS(50μg).

Stabilityofthenucleicacid/invivo-jetPEI^®complexes

Complexesformedbetweennucleicacidsandinvivo-jetPEI^®donotformaggregatesovertimeandthusarestableforatleast24hatRT,4°Cand37°C(Fig.8).

Withstablecomplexes,thenucleicacidisprotectedforlonger,therebyallowingthepreparationofcomplexesinadvanceortheuseofosmoticpumpsforacontinuousdelivery.

Fig.5:Organstargetedfollowingsystemicnucleicaciddeliveryusinginvivo-jetPEI^®inmice.pCMVLuc(50µg)wascomplexedwithinvivo-jetPEI^®in400µlof5%glucosesolutionandinjectedintothetailvein.24haftergenedelivery,organswereextractedandluciferaselevelineachorganwasanalyzedusingaluciferaseassayandexpressedrelativetotheamountoftotalproteins.

Fig.8:nucleicacid/invivo-jetPEI^®complexesarestableovertime.pCMVLuc(40µg)wascomplexedwithinvivo-jetPEI^®.Complexesincubatedfor30minor24hat4°Cwereintravenouslyinjected.BioluminescentimagingoftheanimalswasperformedusingIVIS100bioimagingsystem(Caliper-PerkinElmer)24hafterinjection.

Formoredetails,pleasedownloadtheBioimagingApplicationNoteinAttachedFilesbutton.

Applications:

invivofunctionalstudies

invivo-jetPEI^®isperfectlysuitedtostudygenefunctioninvivoandprovidestheeasiestmethodforthevalidationofinvitrofunctionalstudiesintoanimals.

Readmore…

CancerTherapy

invivo-jetPEI^®-basednucleicaciddeliveryisnowwidelyusedfortumorgrowthinhibitionstudies.Asanexample,thedeliveryofamodifiedsiRNAagainstCyclinB1withinvivo-jetPEI^®inhibitstheformationoflungmetastases(Fig.9A)andinvivo-jetPEI^®mediateddeliveryofamodifiedsiRNAagainstSurvivinpreventsthegrowthofatumorxenograftmodel(Fig.9B).

Readmore…

Immunization/Vaccination

FollowinginvivoadministrationofplasmidDNAformulatedwithinvivo-jetPEI^®,theexpressedproteincanelicittheinductionofarobustandpersistentimmuneresponse,henceprotectinganimalsfromdifferentvirusesorpathogenschallenge.

Readmore…

invivogeneeditingusingCRISPR/Cas9system

invivo-jetPEI^®-mediateddeliveryofCRISPR/Cas9systemtargetingtumorsuppressorgenesprovidesaflexibleandeffectivemethodtoinvestigatesomaticloss-of-functionalterationsandtheirinfluenceontumOrigenesis.

Readmore…

Citations:

Hereisaselectionofrelevantreferencesusinginvivo-jetPEI®,moreareavailableinourPolyplus-transfectionDatabase.Acosta,C.,Djouhri,L.,Watkins,R.,Berry,C.,Bromage,K.,Lawson,S.N.(2014).TREK2expressedselectivelyinIB4-bindingC-fibernociceptorshyperpolarizestheirmembranepotentialsandlimitsspontaneouspain.,JNeurosci34,1494-509.Bivas-Benita,M.,Gillard,G.O.,Bar,L.,White,K.A.,Webby,R.J.,Hovav,A.H.,Letvin,N.L.(2013).AirwayCD8(+)TcellsinducedbypulmonaryDNAimmunizationmediateprotectiveanti-viralimmunity.,MucosalImmunol6,156-6.Ellermeier,J.,Wei,J.,Duewell,P.,Hoves,S.,Stieg,M.R.,Adunka,T.,Noerenberg,D.,Anders,H.J.,Mayr,D.,Poeck,H.,Hartmann,G.,Endres,S.,Schnurr,M.(2013).TherapeuticefficacyofbifunctionalsiRNAcombiningTGF-beta1silencingwithRIG-Iactivationinpancreaticcancer.,CancerRes73,1709-20.Wahlquist,C.,Jeong,D.,Rojas-Munoz,A.,Kho,C.,Lee,A.,Mitsuyama,S.,vanMil,A.,Park,W.J.,Sluijter,J.P.,Doevendans,P.A.,Hajjar,R.J.,Mercola,M.(2014).InhibitionofmiR-25improvescardiaccontractilityinthefailingheart.,Nature508,531-5.Zuckermann,M.,Hovestadt,V.,Knobbe-Thomsen,C.B.,Zapatka,M.,Northcott,P.A.,Schramm,K.,Belic,J.,Jones,D.T.W.,Tschida,B.,Moriarity,B.,Largaespada,D.,Roussel,M.F.,Korshunov,A.,Reifenberger,G.,Pfister,S.M.,Lichter,P.,Kawauchi,D.andGronych,J.(2015).SomaticCRISPR/Cas9-mediatedtumoursuppressordisruptionenablesversatilebraintumourmodelling.,NatCommun6:7391.

Quality:

Polyplus-transfection^®isISO9001QualityManagementSystemaccreditedsince2002;thislevelofcertificationassuresglobalcustomersthatthesupplierhasestablishedreliableandeffectiveprocessesforproductdevelopment,manufacturing,salesandcustomersupport.

Testimonials:

« IfinishedtheexperimentsandIthinkinvivo-jetPEI^®worksgreat.Iamverypleasedwiththeresults.Actuallysomeoftheworkwehavedonewithinvivo-jetPEI^®aswellasjetSI™10mMhasbeenpublishedinScience.[…]Iamalsoverypleasedwiththetechnicalassistance.Manythanks! »

EmineE.K.,HacettepeUniversity,Turkey

« Ourprojectisgoingquitewell,weareworkingalotwithyoursiRNAsdeliverysystem,andweareobtainingsuperbresultsinvivo. »

MattiaC.,L’AquilaUniversity,Italy

« invivo-jetPEI^®isaverynicereagenttoworkwith! »–Marie-LineG.,LadyDavisInstitute,Canada

对照品标准品，生物试剂盒，gibco胎牛血清，试剂采购网，中国试剂网，细胞因子试剂盒

Polyplus Transfection/in vivo-jetPEI®/Polyplus Transfection-163153/1 Ea

Specifications:

Summary:

Orderinginformation:

Description:

SuitableforinvivodeliveryofDNA,siRNA,miRNA,oligonucleotidesandmRNA

Easytwo-stepprotocol

Widerangeofadministrationroutestotargetdifferentorgans

Suitableforanyanimalmodel

Currentlyusedfortherapeuticsandclinicaltrialsworldwide

Safe:noinflammatoryresponsetriggered

Stabilityofthenucleicacid/invivo-jetPEI®complexes

Applications:

invivofunctionalstudies

CancerTherapy

Immunization/Vaccination

invivogeneeditingusingCRISPR/Cas9system

Citations:

Quality:

Testimonials:

Polyplus Transfection/in vivo-jetPEI^®/Polyplus Transfection-163153/1 Ea

Stabilityofthenucleicacid/invivo-jetPEI^®complexes